Sachs Associates’ Post

Introducing Outrun Therapeutics - the E3 ligase inhibitor and protein stabilisation specialist. Outrun launches today with a $10m seed financing round from leading venture capital investors M Ventures and MP Healthcare Venture Management Inc. We are developing a proprietary E3 ligase platform, which enables protein stabilisation "at source", restoring the body's natural disease suppression processes. Our platform has enabled us to rapidly build a promising pipeline of first-in-class, small molecule, E3 ligase inhibitors which can stabilise proteins and treat disease in several therapeutic areas such as #oncology and #neurology. Watch this space! Read more via the link in the comments. #biotech #drugdiscovery #e3ligase #proteinstabilisation

2024 Life Science #IPOs! Key drivers include: Later stage assets and #clinical #trial results. Multiple early stage assets with #platform technology TA Focus: #Oncology / #cancer, #Neuro/ #CNS; #Inflammation/ #Immunology TM focus #smallmolecules, #biologics, #genetherapy, and #celltherapy. The median #IPO is $110M with a high of $380M. #funding #publicofferings #biotech #biopharma Kyverna Therapeutics; CG Oncology; Contineum Therapeutics; Boundless Bio; Chromocell Corporation; Metagenomi; Telomir Pharmaceuticals, Inc.; Alto Neuroscience; Fractyl Health; Autonomix Medical; ArriVent Biopharma #ai #datascience #machinelearning #ML #VC #biopharma #biotech #CFO #ipos

🧠 Advances in Glioblastoma Research: Exploring New Targets Study Overview: Authors: Amandeep Thakur, Dr. Chetna Faujdar, RAM SHARMA M.D. APC, Sachin Sharma, Basant Malik, Kunal Nepali, Jing-Ping Liou Focus: Current status and emerging targets in glioblastoma (GBM) research. Key Insights: Glioblastoma, a highly malignant brain tumor, presents challenges in chemotherapy resistance. The study explores new small-molecule inhibitors with central nervous system (CNS)-penetrating ability for anti-GBM drug discovery. Why It's Important: Offers a perspective on the hurdles in GBM drug discovery and delivery. Highlights potential therapeutic targets and agents under clinical investigation. 🔬 A New Era in GBM Treatment: This study underlines the need for innovative approaches in tackling GBM, providing insights into the latest medicinal chemistry campaigns in this field. 🔗 https://lnkd.in/d7sc3KZs 🏥 #BrainTumorResearch #Glioblastoma #MedicalInnovation #CME

🆕 Wow!! More in the new class of #MolecularGlueDegraders development programs: 🤝 Another molecular glue degraders deal is announced, this one between Takeda and Degron Therapeutics, in oncology, neuroscience, and inflammation, leveraging the latter's "GlueXplorer' technology. Recall other degrader collab announcements, such as Bristol Myers Squibb (w/ Roivant Sciences's VanAI) and Novo Nordisk (w/ Neomorph, Inc.) A few other touchpoints (not exhaustive) on the potential of these molecular glue degraders: 🎯 Targeted Degradation: selectivity/ability to selectively degrade specific disease-associated proteins, allowing precise modulation of protein levels 🔬 Access to Undruggable Targets: a novel approach to tackle previously challenging or “undruggable” protein targets through exploiting protein-protein interactions and utilizing the cellular degradation machinery ⬆ Combination Therapies: may enhance treatment efficacy when used in combination with other therapies https://lnkd.in/eADhm2Wn #Oncology #Innovation #Development #MolecularGlueDegraders #Neuroscience #InflammatoryDisease #Takeda #DegronTherapeutics #CorporateAffairs #Pharma #Healthcare

PulseSight Therapeutics, launched early 2024, is an ophthalmology clinical-stage biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology for AMD. PulseSight has developed a proprietary platform that uses a user-friendly electro-transfection system to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle to treat eye diseases. The company’s lead program PST-611 in GA is ready to enter the clinic by the end of 2024, whilst its second program, PST-809 in wet AMD is at the very late stage of preclinical IND-enabling studies. Both first-in-class candidates benefit from a solid preclinical package showing their ability to address multiple pathological pathways involved in these two forms of AMD, thus providing a higher efficacy compared to current treatments.  First clinical trials have been performed (PST-606 in non-infectious uveitis), showing the very good safety profile of both the plasmid and the delivery procedure as well as the long lasting expression of the therapeutic proteins, allowing to significantly reduce the frequency of injections (4 to 6 months). Pulsesight Therapeutics is managed by a highly experienced executive team and board of Directors; it is financed with seed investment from leading venture capital investors Dominik Escher, PhD, founding partner of Pureos Bioventures and Kostas Kaloulis, PhD, Venture Partner at ND Capital. Meet PulseSight Therapeutics @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy.  We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy. We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Missed episode 2 of our webinar series "Oligonucleotide Therapeutics: Discovery to Development"? Watch it on demand! In this webinar, titled "New Mechanisms and Targets for microRNAs Therapeutics", our guest speaker Dr. David Corey, Rusty Kelley Professor of Biomedical Research, UT Southwestern University, explores the therapeutic potential of miRNA- targeting treatments, outlining cutting-edge research that is identifying new miRNA targets. He also discusses the latest methodologies in miRNA research, including next-generation sequencing and miRNA inhibition. Watch on-demand now! https://hubs.ly/Q02Rtbp20 #microRNA #Therapeutics #Oligonucleotides

https://lnkd.in/gwzFCRCA The insights herein are invaluable for researchers and clinicians interested in the evolving trajectory of this rapidly advancing field. This article is a must-read for those looking to understand the current landscape and future potential of organoid technology. #Organoids #BiomedicalResearch #PersonalizedMedicine #SyntheticBiology #3DCellCulture #CancerResearch The transformative potential of organoids in various biomedical sectors, particularly in oncology, drug discovery, and personalized medicine are in the spotlight. Highlighted is the synergy between organoids and cutting-edge technologies like synthetic biology and AI, illustrating an optimistic future miniature organ models.  We at PearlBioSystem look forward to future studies that build on this foundation, addressing the practical challenges and ethical considerations that accompany exciting advancements in organoid technology.

Excited to share our new research paper on the R&D of cannabinoid therapeutics, published in Redox Biology. Our drug discovery scientists in Dr. Pam Maher's lab at Salk Institute for Biological Studies teaming up with Dr. Kim Finley's lab at San Diego State University, using FBDD and cell-based phenotypic screens, we developed novel CBN analogs with improved CNS druglikeness and neuroprotective activities. The new analogs were also proven to be efficacious in vivo for the increase in survival rates of traumatic brain injury (mTBI) in the Drosophila model. Bravo to the great research team with David Soriano Castell, Wolfgang Fischer, Alec Candib, Kim Finley, Pam Maher! Learn more: Fragment-based drug discovery and biological evaluation of novel cannabinol-based inhibitors of oxytosis/ferroptosis for neurological disorders #mitochondria #aging #neuroprotection #redox #oxytosis #ferroptosis #cannabinoid #cannabis #CBN #drugdiscovery